Prognosis of hematologic malignancies does not predict intensive care unit mortality

Critical Care Medicine

Volumn 30, Issue 10, 2002, Pages 2260-2270

  Massion, Paul B ^a   Dive, Alain M ^a   Doyen, Chantal ^a   Bulpa, Pierre ^a   Jamart, Jacques ^a   Bosly, André ^a   Installé, Etienne ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

Cancer; Critical care; Hematologic malignancy; Leukemia; Lymphoma; Mortality; Organ dysfunction; Prognosis; Scores

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CRITICAL ILLNESS; DISEASE SEVERITY; FEMALE; HEMATOLOGIC DISEASE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MYCOSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE;

EID: 0036800026     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200210000-00014     Document Type: Article

References (84)

1. Brunet F, Lanore JJ, Dhainaut JF, et al: Is intensive care justified for patients with haematological malignancies? Intensive Care Med 1990; 16:291-297
2. Groeger JS, Lemeshow S, Price K, et al: Multicenter outcome study of cancer patients admitted to the intensive care unit: A probability of mortality model. J Clin Oncol 1998; 16:761-770
3. Guiguet M, Blot F, Escudier B, et al: Severity-of-illness scores for neutropenic cancer patients in an intensive care unit: Which is the best predictor? Do multiple assessment times improve the predictive value? Crit Care Med 1998; 26:488-493
4. Price KJ, Thall PF, Kish SK, et al: Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit. Am J Respir Crit Care Med 1998; 158: 876-884
5. Lloyd-Thomas AR, Dhaliwal HS, Lister TA, et al: Intensive therapy for life-threatening medical complications of haematological malignancy. Intensive Care Med 1986; 12: 317-324
6. Lloyd-Thomas AR, Wright I, Lister TA, et al: Prognosis of patients receiving intensive care for lifethreatening medical complications of haematological malignancy. BMJ (Clin Res Ed) 1988; 296:1025-1029
7. Peters SG, Meadows JA III, Gracey DR: Outcome of respiratory failure in hematologic malignancy. Chest 1988; 94:99-102
8. Yau E, Rohatiner AZ, Lister TA, et al: Long term prognosis and quality of life following intensive care for life-threatening complications of haematological malignancy. Br J Cancer 1991; 64:938-942
9. Epner DE, White P, Krasnoff M, et al: Outcome of mechanical ventilation for adults with hematologic malignancy. J Investig Med 1996; 44:254-260
10. Jackson SR, Tweeddale MG, Barnett MJ, et al: Admission of bone marrow transplant recipients to the intensive care unit: Outcome, survival and prognostic factors. Bone Marrow Transplant 1998; 21:697-704
11. Afessa B, Tefferi A, Hoagland HC, et al: Outcome of recipients of bone marrow transplants who require intensive-care unit support. Mayo Clin Proc 1992; 67:117-122
12. Crawford SW, Petersen FB: Long-term survival from respiratory failure after marrow transplantation for malignancy. Am Rev Respir Dis 1992; 145:510-514
13. Rubenfeld GD, Crawford SW: Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: A case for evidence-based guidelines. Ann Intern Med 1996; 125:625-633
14. Ewig S, Torres A, Riquelme R, et al: Pulmonary complications in patients with haematological malignancies treated at a respiratory ICU. Eur Respir J 1998; 12:116-122
15. Staudinger T, Stoiser B, Mullner M, et al: Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med 2000; 28:1322-1328
16. Hinds CJ, Martin R, Quinton P: Intensive care for patients with medical complications of haematological malignancy: Is it worth it? Schweiz Med Wochenschr 1998; 128: 1467-1473
17. Haines IE, Zalcberg J, Buchanan JD: Not-for-resuscitation orders in cancer patients: Principles of decision-making. Med J Aust 1990; 153:225-229
18. Lowenberg B, Downing JR, Burnett A: Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062
19. Arnold R, de Witte T, van Biezen A, et al: Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: An EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 1998; 21:1213-1216
20. Appelbaum FR: Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 1997; 24:114-123
21. Ferrant A, Labopin M, Frassoni F, et al: Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; 90:2931-2938
22. Sasazuki T, Juji T, Morishima Y, et al: Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor: Japan Marrow Donor Program. N Engl J Med 1998; 339:1177-1185
23. Pui CH, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 1998; 339:605-615
24. Ludwig WD, Rieder H, Bartram CR, et al: Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 92:1898-1909
25. Sokal JE, Baccarani M, Tura S, et al: Prognostic discrimination among younger patients with chronic granulocytic leukemia: Relevance to bone marrow transplantation. Blood 1985; 66:1352-1357
26. Kantarjian HM, Giles FJ, O'Brien SM, et al: Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am 1998; 12:31-80
27. Martiat P, Michaux JL, Rodhain J: Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): Comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique. Blood 1991; 78:205-211
28. Gratwohl A, Hermans J, Goldman JM, et al: Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352:1087-1092
29. Passweg JR, Rowlings PA, Horowitz MM: Related donor bone marrow transplantation for chronic myelogenous leukemia. Hematol Oncol Clin North Am 1998; 12:81-92
30. Sawyers CL: Chronic myeloid leukemia. N Engl J Med 1999; 340:1330-1340
31. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052-1057
32. Zwiebel JA, Cheson BD: Chronic lymphocytic leukemia: Staging and prognostic factors. Semin Oncol 1998; 25:42-59
33. Matutes E, Brito-Babapulle V, Swansbury J, et al: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991; 78:3269-3274
34. Hoyer JD, Ross CW, Li CY, et al: True T-cell chronic lymphocytic leukemia: A morphologic and immunophenotypic study of 25 cases. Blood 1995; 86:1163-1169
35. Pettitt AR, Zuzel M, Cawley JC: Hairy-cell leukaemia: Biology and management. Br J Haematol 1999; 106:2-8
36. Johnson S, Smith AG, Loffler H, et al: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia: The French Cooperative Group on CLL, Lancet 1996; 347:1432-1438
37. Khouri IF, Keating MJ, Champlin R: Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Hematol 1998; 5:454-459
38. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-2088
39. Heaney ML, Colde DW: Myelodysplasia. N Engl J Med 1999; 340:1649-1660
40. Myeloma Trialists' Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842
41. Durie BC, Stock-Novack D, Salmon SE, et al: Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: A Southwest Oncology Group Study. Blood 1990; 75: 823-830
42. Bataille R, Harousseau JL: Multiple myeloma. N Engl J Med 1997; 336:1657-1664
43. Riccardi A, Mora O, Brugnatelli S, et al: Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: Updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 1998; 77:485-491
44. Lokhorst HM, Sonneveld P, Verdonck LF: Intensive treatment for multiple myeloma: Where do we stand? Br J Haematol 1999; 106:18-27
45. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-1514
46. Aisenberg AC: Problems in Hodgkin's disease management. Blood 1999; 93:761-779
47. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-1392
48. Krueger GR, Medina JR, Klein HO, et al: A new working formulation of non-Hodgkin's lymphomas: A retrospective study of the new NCI classification proposal in comparison to the Rappaport and Kiel classifications. Cancer 1983; 52:833-840
49. Shipp MA, Harrington DP, Anderson JR: A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994
50. Bastion Y, Blay JY, Divine M, et al: Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival. A Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 1997; 15:2945-2953
51. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-2795
52. Gianni AM, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MA-COP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336:1290-1297
53. Blay J, Gomez F, Sebban C, et al: The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Parma Group. Blood 1998; 92:3562-3568
54. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermed. N Engl J Med 1998; 339:21-26
55. Boussiotis VA, Freedman AS, Nadler LM: Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Semin Hematol 1999; 36:209-216
56. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829
57. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957-2963
58. Marshall JC, Cook DJ, Christou NV, et al: Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1652
59. Le Gall JR, Klar J, Lemeshow S, et al: The Logistic Organ Dysfunction system: A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. JAMA 1996; 276:802-810
60. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
61. Cox DR: Regression models and life-tables. J R Stat Soc 1972; 34:187-202
62. McCabe WR, Jackson GG: Gram negative bacteremia: Etiology and ecology. Arch Intern Med 1962; 110:847-852
63. Blot F, Guiguet M, Nitenberg G, et al: Prognostic factors for neutropenic patients in an intensive care unit: Respective roles of underlying malignancies and acute organ failures. Eur J Cancer 1997; 33:1031-1037
64. Groeger JS, White P Jr, Nierman DM, et al: Outcome for cancer patients requiring mechanical ventilation. J Clin Oncol 1999; 17: 991-997
65. Azoulay E, Recher C, Alberti C, et al: Changing use of intensive care for hematological patients: The example of multiple myeloma. Intensive Care Med 1999; 25:1395-1401
66. Torrecilla C, Cortes JL, Chamorro C, et al: Prognostic assessment of the acute complications of bone marrow transplantation requiring intensive therapy. Intensive Care Med 1988; 14:393-398
67. Bach PB, Schrag D, Nierman DM, et al: Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. Blood 2001; 98:3234-3240
68. Huaringa AJ, Leyva FJ, Giralt SA, et al: Outcome of bone marrow transplantation patients requiring mechanical ventilation. Crit Care Med 2000; 28:1014-1017
69. Horning SJ: Follicular lymphoma: Have we made any progress? Ann Oncol 2000; 11(Suppl 1):23-27
70. Moreno R, Vincent JL, Matos R, et al: The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care: Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ES-ICM. Intensive Care Med 1999; 25:686-696
71. Jacobs S, Zuleika M, Mphansa T: The Multiple Organ Dysfunction Score as a descriptor of patient outcome in septic shock compared with two other scoring systems. Crit Care Med 1999; 27:741-744
72. Hutchinson C, Craig S, Ridley S: Sequential organ scoring as a measure of effectiveness of critical care. Anaesthesia 2000; 55: 1149-1154
73. Vincent JL, Ferreira F, Moreno R: Scoring systems for assessing organ dysfunction and survival. Crit Care Clin 2000; 16:353-366
74. Marshall JC: Charting the course of critical illness: prognostication and outcome description in the intensive care unit. Crit Care Med 1999; 27:676-678
75. Marshall JC: Organ dysfunction as an outcome measure in clinical trials. Eur J Surg Suppl 1999:62-67
76. Janssen JJ, Strack van Schijndel RJ, van der Poest Clement EH, et al: Outcome of ICU treatment in invasive aspergillosis. Intensive Care Med 1996; 22:1315-1322
77. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328:1323-1332
78. Empiric antifungal therapy in febrile granulocytopenic patients: EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989; 86:668-672
79. Malik IA, Moid I, Aziz Z, et al: A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am JMed 1998; 105:478-483
80. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al: Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44: 1887-1893
81. Bulpa PA, Dive AM, Garrino MG, et al: Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: Benefits of intensive care? Intensive Care Med 2001; 27:59-67
82. Schapira DV, Studnicki J, Bradham DD, et al: Intensive care, survival, and expense of treating critically ill cancer patients. JAMA 1993; 269:783-786
83. Sculier JP, Paesmans M, Markiewicz E, et al: Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit. Crit Care Med 2000; 28: 2786-2792
84. Withholding and withdrawing life-sustaining therapy: This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, March 1991. Am Rev Respir Dis 1991; 144:726-731